SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Accrued Liabilities
SCI Pharmtech Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Accrued Liabilities
NT$99m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
1%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Accrued Liabilities
NT$627.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
23%
|
CAGR 10-Years
11%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Accrued Liabilities
NT$143.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Accrued Liabilities?
Accrued Liabilities
99m
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Accrued Liabilities amounts to 99m TWD.
What is SCI Pharmtech Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
1%
Over the last year, the Accrued Liabilities growth was 21%. The average annual Accrued Liabilities growth rates for SCI Pharmtech Inc have been 9% over the past three years , -8% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet